CRDF (Cardiff Oncology, Inc.) Net earnings per share growth this year

CRDF (Cardiff Oncology, Inc.) - company brandmark

Cardiff Oncology, Inc. (CRDF) plans to monetize its PLK1 inhibitor for the treatment of prostate and colorectal cancers by developing partnerships with medical networks to implement new standards of care. The year-over-year EPS trend, as shown on GURU.Markets, has stabilized at 18.50. The company's strategy is based on the expansion of targeted drugs against metastases with the goal of subsequently selling them to pharmaceutical behemoths.

Earnings per share growth in current year: Cardiff Oncology Inc. (CRDF) for 07/04/2022 - 11/17/2026

Financial and market metric breakdowns for Cardiff Oncology Inc. (CRDF)

Summary company analysis:CRDF Cardiff Oncology
Signature product of Cardiff Oncology

This indicator measures the annual change in net income per share, allowing investors to assess the growth rate of the business's real earnings relative to the previous year. By analyzing the annual net income per share dynamics through GURU.Markets tools, one can confirm the stability of Cardiff Oncology, Inc. (CRDF), whose development of targeted drugs within the West's protected legal framework minimizes sanction risks.

Key competitors

Earnings per share growth this year INCY|Earnings per share growth in current year Hutchison MediPharma|Net earnings per share growth this year nuvationbio.com (NUVB)|Earnings per share growth in current year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences Inc INBX|I-Mab - Earnings per share growth in current year|FENC - Earnings per share growth in current year|Earnings per share growth rate in current year herontx.com|NVCT: Earnings growth in current year|Net earnings per share change in current year Coherus CHRS|Net earnings per share growth this year CRBP|Earnings per share growth rate in current year BeyondSpring Inc. BYSI|Net earnings per share growth this year BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Earnings per share increase in current year|Citius Pharmaceuticals, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma, Ltd.)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia (KZIA)|Earnings per share growth in current year silexion.com|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year Oncternal Therapeutics Inc|Portage Biotech (PRTG) - Earnings per share growth in current year